Glaukos (NYSE:GKOS) announced today that the FDA approved a new drug application (NDA) labeling supplement for its iDose TR ...

Glaukos shares were 6% higher, at $125.46, Wednesday after the Food and Drug Administration approved a new drug application labeling supplement allowing for re-administration of iDose TR using a ...

Glaukos Corporation (GKOS) added ~7% on Wednesday after the U.S. Food and Drug Administration approved a labeling change for ...

Results from the iDose TR exchange trial showed a second administration and removal of the original implant was safe and well tolerated over 12 months.

The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced ...

Glaukos Corporation (NYSE:GKOS) stock climbed 6.3% on Wednesday after the company announced that the U.S. Food and Drug ...

Shares of Glaukos retreated after the company forecast disappointing sequential revenue growth for its iDose product in the fourth quarter. The stock declined 12% to $97 in after-hours trading on ...

iDose TR helps patients with glaucoma take long-term control of high eye pressure. WILMINGTON, NC / ACCESSWIRE / May 28, 2024 / Wilmington Eye is proud to announce the availability of iDose® TR ...

SAN FRANCISCO — The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker here. Designed ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Commercial launch ...